TRADEMARK

Nizoral

(ketoconazole) tablets

over 5 million prescriptions world-wide.

Oral medication in antifungal therapy:

Doctors and patients around the world are discovering the modern simplicity of Nizoral oral therapy. Common but often problematic fungal infections can now be treated effectively *and elegantly*.

Typically, in *Candida* vaginitis, 2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem.

JANSSEN PHARMACEUTICA

the drug discovery company

Prescribing Information

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I.-tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed. **Side-effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H_2-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long-term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances, gynaecomastia has been reported.

Inhaled steroid strength in severe chronic asthma

Laocoön, priest of Troy, with his two sons struggles against the serpents sent by Apollo.
Reproduced by kind permission of BBC Hulton Picture Library.

BECLOFORTE

(Beclomethasone Dipropionate BP)

High strength, inhaled steroid therapy

Prescribing information Uses For those asthmatic patients requiring greater than 800 to 1,000μg beclomethasone dipropionate daily or patients with severe asthma dependent on systemic corticosteroids. **Dosage and administration – Adults:** two inhalations (500μg) twice daily, or one inhalation (250μg) four times daily. If necessary, dosage may be increased to two inhalations (500μg) three or four times daily. **Contra-indications** Hypersensitivity to Becloforte Inhaler. Special care is necessary in patients with active or quiescent pulmonary tuberculosis. Unnecessary administration of drugs during the first trimester of pregnancy is undesirable. **Precautions** Patients on high doses of Becotide may be transferred directly to Becloforte. In most patients, no significant adrenal suppression occurs until daily doses of 1,500μg are exceeded. Some patients on 2,000μg daily may exhibit some suppression but maintain their short-term adrenal reserve. The latter risk should be balanced against therapeutic advantages and systemic steroid cover provided in situations of prolonged stress. Patients currently on oral steroids should be stable before adding Becloforte. Gradual withdrawal of oral steroids may be attempted after 7 to 14 days. Adrenocortical function should be monitored in patients previously or currently on prolonged or high dose systemic steroids. Treatment with Becloforte should not be stopped abruptly. **Side effects** Occasional oropharyngeal candidiasis occurs in some patients. Topical antifungal therapy usually clears the condition without discontinuation of Becloforte. **Presentation and Basic NHS cost** Becloforte Inhaler is a metered-dose aerosol delivering 250μg Beclomethasone Dipropionate BP per actuation. Basic NHS cost £21·00. **Product licence number** 0045/0125.

Further information is available on request from: Allen & Hanburys Limited, Greenford, Middlesex UB6 0HB. Becloforte and Becotide are trade marks

AUGMENTIN

clavulanate-potentiated amoxycillin

A MAJOR DEVELOPMENT IN ANTIBIOTIC THERAPY



In recent years, the treatment of infection has been complicated by the increasing prevalence of ß-lactamase producing strains of bacteria. ß-lactamase destroys many oral cephalosporins and penicillins,[1,2] resulting in treatment failure.

AUGMENTIN is the first antibiotic to utilise Beecham's discovery of the powerful ß-lactamase inhibitor, clavulanic acid. This neutralises the bacterial defence, bringing more strains and species within the scope of oral therapy.

- **AUGMENTIN – Broader in spectrum** than oral cephalosporins, co-trimoxazole, ampicillin, tetracycline or erythromycin.
- **AUGMENTIN – Outstanding success** against today's infections.

Adult infections	No. of patients assessed	Clinically cured/ improved	Clinical success
Upper respiratory tract[3]	146	141	**97%**
Lower respiratory tract[3]	98	89	**91%**
Urinary tract[3]	175	167	**95%**
Skin & soft tissue[3,4]	81	75	**93%**

Paediatric infections	No. of patients assessed	Clinically cured/ improved	Clinical success
Upper respiratory tract[5,6]	70	70	**100%**
Lower respiratory tract[7]	28	27	**96%**
Urinary tract[6,7,8]	61	57	**93%**

PRESCRIBING INFORMATION

INDICATIONS: Chest, ear, nose, throat, genito-urinary, skin and soft tissue infections including those caused by ß-lactamase producing organisms. **DOSAGE: Adults and children over 12 years** one AUGMENTIN tablet (375mg) three times daily. **Children 7-12 years** 10ml AUGMENTIN syrup (312mg) three times daily. **Children 2-7 years** 5ml AUGMENTIN syrup (156mg) three times daily. **Children 9 months – 2 years** 2.5ml AUGMENTIN syrup (78mg) three times daily. In severe infections these dosages may be doubled. Treatment should not be extended beyond 14 days without review. **CONTRA-INDICATION:** Penicillin hypersensitivity. **PRECAUTIONS:** Safety in human pregnancy is yet to be established. Oral dosage need not be reduced in patients with renal impairment unless dialysis is required. **SIDE-EFFECTS:** Uncommon, mainly mild and transitory, eg diarrhoea, indigestion, nausea, vomiting, candidiasis, urticarial and morbilliform rashes. If gastro-intestinal side-effects do occur they may be reduced by taking AUGMENTIN at the start of meals. **PRESENTATIONS:** 375mg AUGMENTIN tablets each containing 250mg amoxycillin (1) and 125mg Clavulanic acid. (2) 156.25mg AUGMENTIN syrup. Powder for preparing fruit flavoured syrup. When dispensed each 5ml contains 125mg amoxycillin (1) and 31.25mg clavulanic acid. (2) (1) as the trihydrate, (2) as the potassium salt. Not all presentations are available in every country.

Further information is available from:

Beecham Research Laboratories
Brentford, Middlesex, England.

References 1. Proc. Int. Symp. on AUGMENTIN, Excerpta Med. (1980), **ICS 544**, 173. 2. Excerpta Med. (1980), **ICS 544**, 19. 3. Excerpta Med. (1980), **ICS 544**, 187. 4. Scot. Med. J., (1982), **27**, 535. 5. Proc. Europ. Symp. on AUGMENTIN, Excerpta Med. (1982), **CCP4**, 341. 6. Excerpta Med. (1982), **CCP4**, 347. 7. Excerpta Med. (1982), **CCP4**, 325. 8. Excerpta Med. (1982), **CCP4**, 334.

ADALAT® RETARD:
ANTIHYPERTENSIVE
WITH CARDIOPROTECTIVE EFFECT

Long term therapy with Adalat retard
- reduction in peripheral vascular resistance
- reduction in high blood pressure (reliable reduction in pathologically high blood pressure)
- permanent relief of the heart
- improvement of the myocardial oxygen balance
- protection of cell against unphysiological noxious Ca^{++} concentrations in case of a pathological ion overflow.

E 4/042

THE MODERN COMPREHENSIVE DRUG THERAPY OF CARDIOVASCULAR DISEASE: ADALAT RETARD.

Composition: **1 tablet Adalat® retard contains 20 mg nifedipine.** Indications: Coronary heart disease. Early and long term treatment of coronary heart disease (in particular coronary insufficiency, angina pectoris, post-infarction syndrome). All forms of hypertension. Contraindication: Pregnancy. Side effects: Side effects occur only rarely and, if at all, at the beginning of treatment, they are usually mild and transient. Occasional symptoms may be headache, facial flush and heat sensation, leg oedema, nausea, dizziness, tiredness and skin reactions. As is the case with other vasoactive substances, chest pain may very occasionally occur after administration. In this event Adalat should be discontinued if the pains are considered to have been caused by the medication. Interactions: Adalat can be administered together with antihypertensive agents, however, the additive effect should be taken into account. Treatment with cardiac glycosides can be begun or continued during nifedipine treatment. A combination treatment of Adalat retard with beta blockers or a saluretic is possible (see S.M.L.). ● Dosage: Treatment should be adjusted individually to the degree of severity of the disease and to the patient's responsiveness. A daily dose of 2 x 1 tablet of Adalat retard (2 x 20 mg) is recommended. In individual cases an increase in the daily dose to 2 x 2 tablets of Adalat retard (2 x 40 mg) may be necessary. The recommended interval between tablet intake is about 12 hours and should not be shorter than 4 hours. Generally, the tablet is swallowed unchewed with a little liquid, independent of meals. Note: In the presence of coronary spasms (Prinzmetal angina, angina at rest) and particularly severe forms of coronary heart disease or in the case of impending anginal attack or acute hypertensive crisis which all require a quick onset of effect, Adalat capsules which are marked by rapid action should be taken chewed. When the patient's condition has improved, a change-over to Adalat retard tablets may be attempted. Presentation: Tablets of 20 mg Nifedipine. Box of 30 tablets, box of 50 tablets, box of 100 tablets, hospital-size pack.

ADALAT RETARD
ANTIHYPERTENSIVE
WITH CARDIOPROTECTIVE EFFECT

Bayer Germany

BAYER